
ArcticZymes Technologies Reports Q2 and H1 2025 Results: Biomanufacturing Growth Accelerates as Customer centric Strategy Gains Momentum
Tromsø, Norway, August 14, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the second quarter of 2025, highlighting progress in the Company’s commercial transformation. Total revenues reached NOK 28.9 million, up 5% year-over-year, led by strong 52% growth in the Biomanufacturing segment which contributed NOK 18.1 million. The quarter also marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a product developed in direct response to customer needs. M-SAN HQ GMP enables broader integration into viral vector manufacturing and reinforces ArcticZymes’ role as a reliable partner in gene therapy workflows.

ArcticZymes Technologies ASA Q4 2024 Results & Presentation
Tromsø, Norway, February 13th, 2025 – ArcticZymes Technologies (OSE: AZT) reported total revenues of NOK 26.4 million and an EBITDA of NOK 2.7 million for the fourth quarter of 2024.

ArcticZymes Expands SAN HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers
Tromsø, Norway – December 9, 2024 – ArcticZymes Technologies ASA (OSE: AZT) ArcticZymes introduces two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector.

ArcticZymes' M-SAN HQ Sets New Standard for Measles Virus Purification with Unmatched DNA Clearance & High Recovery Rates
Tromsø, Norway – November 21, 2024 – ArcticZymes Technologies ASA (OSE: AZT), is proud to highlight the exceptional performance of our M-SAN HQ nuclease in the purification of recombinant measles viruses (MV), as detailed in a recent publication in the Journal of Chromatography A.